Execute Clinical Trial Feasibility with Precision

Optimize your study's initiation through precise country and site selection, powered by actionable insights.

At Precision, our feasibility process is more than just a preliminary step; it's a critical foundation for the success of your clinical trial. By focusing on strategic site selection and in-depth insights gathering, we ensure your study starts with a significant advantage.

Plan for success with Site Feasibility

Site feasibility is the cornerstone of clinical trial planning, acting as the bridge between groundbreaking research and its successful execution. Understanding the pivotal role of site feasibility ensures a solid foundation for any clinical study. It's not merely about identifying potential sites but about strategic alignment with the trial's objectives, patient populations, and operational capacities. This proactive approach to site selection, grounded in data-driven insights and comprehensive evaluations, mitigates risks and sets the stage for successful patient enrollment and study outcomes.

Roughly 80% of clinical trials fail to meet original enrollment timelines, and about one-third of Phase III study terminations are due to enrollment difficulties. Additionally, 15% to 20% of sites never enroll a single patient.

Given these statistics, it's evident that conducting a comprehensive feasibility study is essential for avoiding common pitfalls like poor enrollment and sites that never enroll. Precision's feasibility team employs multiple methods to ensure a sponsor's needs are met, tailoring our approach to each unique trial. This adaptability, combined with a deep understanding of the intricacies of clinical trials, allows Precision to navigate complex requirements and ensure trials are set up for success from the start.

Precision's Clinical Trial Feasibility process overview

Step 1

Initial Planning

Understand study objectives
Identify target countries/sites
Develop feasibility questionnaire
Augment site list with Precision/external data
Site list finalized for feasibility start

Step 2

Data Collection & Analysis

Distribute questionnaires
Pursue sites for response
Collect sites responses
Evaluate sites performance
Prepare feasibility report
Review report with client
Filter out low-potential sites

Step 3

Recruitment Modeling

Develop enrollment scenarios
Estimate recruitment timelines
Project patient numbers
Adjust site requirements
Plan for contingencies
Present models to clients

Step 4

Site Selection & Verification

Confirm top-performing sites
Schedule pre-study visits
Verify site infrastructure
Assess staff expertise
Determine recruitment potential
Finalize site list for activation
Finalize back-up site list

Step 5

Performance Monitoring

Regular progress check-ins
Address emerging issues
Adjust recruitment plans
Activate backup sites
Ensure timeline adherence
Provide ongoing support

Our approach to site feasibility is both comprehensive and meticulous. By integrating broad data analysis with site-specific insights, we ensure each trial starts on the best possible footing. Our process begins with understanding study objectives and identifying optimal countries and sites, followed by developing and distributing targeted feasibility questionnaires. We then analyze site responses and performance, preparing detailed feasibility reports for client review. Through recruitment modeling, we project patient numbers and timelines, allowing for adjustments and contingency planning. Site selection is confirmed through pre-study visits and infrastructure verification, with backup sites identified for risk mitigation. Continuous performance monitoring ensures adherence to timelines and proactive issue resolution, backed by ongoing support. This strategic and detailed approach enables our sponsors to navigate trial complexities with confidence, ensuring successful study execution.

Our site feasibility services can be executed during pre-study phases or integrated into full study start-up processes. This flexibility allows us to adapt to each sponsor's unique requirements, providing tailored support that aligns with their specific clinical trial needs.

It's rare to encounter a feasibility report that's both thoughtfully constructed and substantial. The presentation of the feasibility results was particularly effective, providing clarity that guided our decision-making process and was undeniably enlightening. I appreciate your team’s efforts in managing various adjustments and ensuring robust participation from the sites.

— Head of Operations, Small Biotech
We have been delighted with the experience level and work product from the entire project team – they feel like an extension of our internal team.

— Director, Midsize Pharma
I recognize that relations between Sponsors and CRO vendors can be strained and difficult, often a blaming game; this has never been my experience with this group as it truly felt like a partnership.

— Director, Small Biotech
Our partnership with Precision is a true textbook definition of a great collaboration between a sponsor and a CRO.

— Senior Director, Midsize Biotech

Insights from Precision’s experts

Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies to navigate early and late phase development.

Explore our blog

Clinical Trials

Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan

Apr 03, ‘26 | 5 min read

has third author: false, (SizeLimitingPyMap: {main={hs_id=199521241215, hs_child_table_id=0, hs_updated_at=1774887081250, hs_published_at=1774960708819, description=An industry veteran with nearly three decades of experience in the clinical research industry and deep expertise in clinical operations and strategic leadership across both pharmaceutical and CRO environments. Held pivotal roles as Head of Clinical Operations for Greater China at Boehringer Ingelheim, leading trials in oncology, respiratory, stroke, and cardio-metabolic diseases and CEO of George Clinical, a global CRO with strong scientific capabilities in renal and oncology therapeutic areas. At Precision for Medicine, a leader for business strategy across the Asia Pacific region. Focused on driving regional growth, building strategic partnerships, and supporting excellence in portfolio delivery and client satisfaction. An acknowledged driver of precision-driven solutions that improve patient outcomes., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/James%20Cheong.png',altText='James Cheong',fileId=199519079710}, linkedin=https://www.linkedin.com/in/james-cheong-36a543a/, lastname=Cheong, hs_initial_published_at=1762885727645, hs_created_by_user_id=78347666, hs_created_at=1762885637470, hs_is_edited=false, hs_deleted_at=0, name=James, job=Senior Vice President, Asia Pacific, Clinical Solutions, slug=james-cheong, hs_updated_by_user_id=65160865}, second={hs_id=199519203221, hs_child_table_id=0, hs_updated_at=1770145994248, hs_published_at=1774960708819, description=Highly accomplished global clinical operations executive with nearly three decades of experience providing strategic leadership, regional expansion, and operational excellence across Asia Pacific. Brings deep expertise across clinical development, project and portfolio operations, biometrics, regulatory affairs, safety and pharmacovigilance, quality management, and financial governance. Proven builder and scaler of high‑performing teams and start‑up operations in both regional and global environments. Recognized industry leader who actively contributes to advancing clinical research standards through advisory and governance roles across Asia., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Jing%20Ping%20Yeo.png',altText='Jing Ping Yeo',fileId=199530854290}, linkedin=https://www.linkedin.com/in/jing-ping-yeo/, lastname=Yeo, PhD , hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893091367, hs_is_edited=false, hs_deleted_at=0, name=Jing Ping, job=Vice President, Clinical Operations, Head of Asia Pacific, slug=JingPing-Yeo, hs_updated_by_user_id=65160865}, third={hs_id=199528025104, hs_child_table_id=0, hs_updated_at=1774885968488, hs_published_at=1774960708819, description=With 20+ years of experience in the clinical trial industry, he has led project management, clinical operations, and business development teams. Prior to joining Precision, he served as the General Manager of Emerald (formerly George Clinical) China, and held project management and business development leadership roles at ICON, WuXi CDS, IQVIA, and KUNTUO. He has successfully led teams to complete more than 120 Phase I–IV clinical trials, many of which were MRCT studies across Asia‑Pacific, Australia, and the United States. He holds a Master’s degree in Urology from Peking University First Hospital., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Zhenfei%20Yin.png',altText='Zhenfei Yin',fileId=199530854553}, lastname=Yin, hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893190542, hs_is_edited=false, hs_deleted_at=0, name=Zhenfei, job=China Country Head, Senior Director, Project Management, slug=Zhenfei Yin, hs_updated_by_user_id=65160865}})

James C.

Jing Ping Y.

Zhenfei Y.

Discover

Clinical Trials - Oncology

Strategic Management of Radiopharmaceutical Trial Complexity

Apr 01, ‘26 | 7 min read

Robert Bauer

Discover

Clinical Trials - Regulatory

What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs

Mar 13, ‘26 | 5 min read

has third author: false, (SizeLimitingPyMap: {main={hs_id=195804116748, hs_child_table_id=0, hs_updated_at=1764696930757, hs_published_at=1774960708819, description=John is an experienced regulatory affairs consultant with more than 15 years of professional experience in drug development. He brings a proven track record in providing regulatory strategy, regulatory document development and review, and liaising with regulatory authorities., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/John%20McIntyre.png',altText='John McIntyre',fileId=201584594055}, lastname=McIntyre, PhD, hs_initial_published_at=1757516163742, hs_created_by_user_id=26433386, hs_created_at=1757515873736, hs_is_edited=false, hs_deleted_at=0, name=John, job=Senior Director, Regulatory Strategy, slug=john-mcintyre, hs_updated_by_user_id=65160865}, second={hs_id=195821592097, hs_child_table_id=0, hs_updated_at=1757598947835, hs_published_at=1774960708819, description=An expert in hematology and oncology and a veteran of the FDA with almost nine years of experience, culminating as a Deputy Director for the Division of Hematologic Malignancies 2. Possesses a profound understanding of regulatory strategy, particularly in the development of CAR-T cell therapies, bispecifics and T-cell engagers. Spearheaded initiatives to develop novel endpoints in blood cancer such as minimal residual disease (MRD) in lymphoma and chronic lymphocytic leukemia (CLL.), avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Nicholas%20Richardson.png',altText='Nicholas Richardson',fileId=195817841672}, linkedin=https://www.linkedin.com/in/nicholas-richardson-do-mph-049784113/, team=[{id=163080551773, name='Clinical Solutions Leadership'}], lastname=Richardson, DO, MPH, hs_initial_published_at=1757528527317, hs_created_by_user_id=51739740, hs_created_at=1757528274871, hs_is_edited=false, hs_deleted_at=0, name=Nicholas, job=Vice President, Clinical Development, slug=nicholas-richardson-clinical-solutions, hs_updated_by_user_id=65160865}, third={hs_id=178046423372, hs_child_table_id=0, hs_updated_at=1754641388766, hs_published_at=1774960708819, description=Rosamund (Roz) Round is a seasoned expert in patient engagement and innovation bringing over 20 years of experience. She is focused on listening to and learning from patients and care partners to understand how to better improve trial access and experience. Roz successfully built and led decentralized clinical trials service through the pandemic and is now addressing the implementation of AI across various aspects of clinical research. She has a strong focus on diversity, equity, and inclusion (DEI) to drive health equity in clinical research. Roz holds an MSc in Health Psychology, studied Psychology and Immunology at Harvard University, and is a recognized thought leader with an extensive portfolio of publications, conference presentations, webinars, and vlogs., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Round-Rosamund.png',altText='Round-Rosamund',fileId=194123714174}, lastname=Round, hs_initial_published_at=1725972637852, hs_created_by_user_id=51739740, hs_created_at=1725972446462, hs_is_edited=false, hs_deleted_at=0, name=Rosamund, job=Vice President, PAtient Engagement & Innovation, slug=rosamund-round, hs_updated_by_user_id=65160865}})

John M.

Nicholas R.

Rosamund R.

Discover

Advance therapeutic breakthroughs with Precision

Explore the breadth of our expertise in therapeutics and modalities, as we lead your novel treatments in Oncology, Rare Diseases and beyond, from the groundbreaking idea to clinical realization.

Oncology Explore

Rare diseases Explore

Autoimmune Explore

Gene Therapy Explore

Cell Therapy Explore

Explore

Early Phase Excellence

Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.

Explore

Early Phase Excellence

Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.

Explore
Explore

Late Phase Success

Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.

Explore

Late Phase Success

Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.

Explore

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

Discover Explore

Global CRO
Services

Award-winning CRO with deep oncology and rare disease expertise

Explore
Discover Explore

Global Laboratory
Services

Exceptional translational and biomarker sciences with global central lab services

Explore

Biospecimens

Discover Biospecimens
Diagnostics & CDx

Discover Diagnostics & CDx
Data Intelligence

Discover Data Intelligence
Commercialization

Discover Commercialization

Execute Clinical Trial Feasibility with Precision

Plan for success with Site Feasibility